• For Individuals
  • For Institutions
  • Download
  • Help

  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文（廣東話）Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials

Event Tracking

Oct31
Astellas Pharma (ADR) Soars in Net Profit by 101% in First Half
00:17
Oct30
Astellas Pharma released FY2026 Semi-Annual Earnings on October 30 After-Market (EST), Actual Revenue: USD 7.023 B (Forecast: USD 6.36 B), Actual EPS: USD 0.5602
23:00
Astellas Pharma released FY2026 Q2 earnings on October 30 After-Market EST, actual revenue USD 3.528 B (forecast USD 3.232 B), actual EPS USD 0.2964
23:00
Astellas Pharma Raises FY2025 Profit Guidance
11:27
Oct26
Pfizer and Astellas Announce Final Overall Survival Results of XTANDI Combined Therapy for Prostate Cancer Study
11:50
Oct23
Astellas Pharma and Barbara Collaborate to Raise Awareness of GA and Izervay
18:37

Schedules & Filings

Schedules
Filings
Oct30
Earning Release(EST)

FY2026 Q2 Earning Release (USD) Revenue 3.528 B, Net Income 532.95 M, EPS 0.2964

Sep30
Distribution Plan(EST)

Cash dividend 0.2698 USD

Distribution Plan(EST)

Cash dividend 0.2698 USD

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0493
+77.34%
+0.021
FOXX
3.540
+75.16%
+1.519
PTN
22.820
+57.49%
+8.330
MNDR
4.750
+56.25%
+1.710
NVVE
0.2558
+55.88%
+0.092
DVLT
2.550
+46.55%
+0.810
CCTG
0.2364
+43.01%
+0.071
IVDA
0.8760
+34.67%
+0.226
BLMZ
1.000
+30.55%
+0.234
ALPS
1.180
+29.56%
+0.269
View More
Terms & Conditions
  • Terms of Service
  • Privacy Policy